Table III.
Differences in blood biochemistry during and following daclatasvir/asunaprevir therapy.
| Factor | Baseline | 12 weeks | EOT | SVR24 | P-value |
|---|---|---|---|---|---|
| AST (IU/l) | 41.43±19.40 | 26.14±9.48a | 24.46±7.71a | 22.57±7.05a | <0.01 |
| ALT (IU/l) | 36.14±20.48 | 20.07±11.69a | 17.61±7.41a | 15.32±7.30a | <0.01 |
| Hb (g/dl) | 12.54±2.18 | 12.56±2.21 | 12.53±2.38 | 12.39±2.67 | 0.72 |
| PLT (×104/µl) | 15.26±8.55 | 15.47±7.70 | 15.49±7.67 | 17.14±9.25a | <0.01 |
| Fib-4 | 5.28±5.19 | 3.79±2.77a | 3.63±2.62a | 3.40±2.33a | <0.01 |
| ALB (mg/dl) | 3.80±0.42 | 3.87±0.40 | 3.92±0.30 | 3.99±0.41a | <0.01 |
| AFP (ng/ml) | 4.90 (3.08, 8.93) | 2.80 (2.38, 5.92)a | 2.85 (2.30, 5.43)a | 3.05 (2.40, 5.45)a | <0.01 |
| eGFR (ml/m/1.73 m2) | 70.54±23.95 | 66.12±22.22 | 66.35±21.98 | 66.43±21.77 | <0.05 |
Data are expressed as the mean ± standard deviation, or median (interquartile range).
a
P<0.05 vs. baseline. Data analyses were performed using the Friedman-test and Bonferroni's multiple comparison correction. DCV/ASV, daclatasvir/asunaprevir; 12 weeks, following 12 weeks of DCV/ASV therapy; EOT, the end of treatment; SVR24, sustained virologic response week 24; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Hb, hemoglobin; PLT, platelet count; Fib-4, fibrosis-4 score; ALB, serum albumin; AFP, α-fetoprotein; eGFR, estimate glomerular filtration rate.